A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 148 participants.

Also called NCT05930028

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 148 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05930028
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05930028. Randomized; double masking; primary purpose treatment. Start 2023-07-13 (actual); primary completion 2024-09-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia
Condition
Essential Hypertension
Condition
Primary Hypercholesterolemia
Intervention (Drug)
Fimasartan
Intervention (Drug)
Ezetimibe/Atorvastatin
Intervention (Drug)
Fimasartan Placebo
Intervention (Drug)
Ezetimibe/Atorvastatin Placebo
Lead sponsor
Boryung Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct05930028
Content hash
a3c59d2f97e300ad25a57b1ffff13695502c1b4552499391f1915a732acc1340